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Abstract 
Background: psychomotor agitation (PA) or retardation (PR) during major depressive 
episodes (MDEs) have been associated with depression severity in terms of treatment-
resistance and course of illness. 
 
Objectives: we investigated the possible association of psychomotor symptoms (PMSs) 
during a MDE with clinical features belonging to the bipolar spectrum. 
 
Methods: the initial sample of 7689 MDE patients was divided into three subgroups 
based on the presence of PR, PA and non-psychomotor symptom (NPS). Univariate 
comparisons and multivariate logistic regression models were performed between 
subgroups. 
Results: 3720 patients presented PR (48%), 1971 shown PA (26%) and 1998 had NPS 
(26%). In the PR and PA subgroups, the clinical characteristics related to bipolarity, 
along with the diagnosis of Bipolar Disorder (BD), were significantly more frequent 
than in the NPS subgroup. When comparing PA and PR patients, the former presented 
higher rates of bipolar spectrum features, such as family history of BD (OR=1.39, 
CI=1.20-1.61), manic/hypomanic switches with antidepressants (OR=1.28, CI=1.11-
1.48), early onset of first MDE (OR=1.40, CI=1.26-1.57), atypical (OR=1.23, CI=1.07-
1.42) and psychotic features (OR=2.08, CI=1.78-2.44), treatment with mood-stabilizers 
(OR=1.39, CI=1.24-1.55), as well as a BD diagnosis according to both the DSM-IV 
criteria and the bipolar specifier criteria. When logistic regression model was 
performed, the clinical features that significantly differentiated PA from PR were early 
onset of first MDE, atypical and psychotic features, treatment with mood-stabilizers and 
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Conclusions: PMSs could be considered as markers of bipolarity, illness severity, and 
treatment complexity, particularly if PA is present.  
 





Psychomotor Symptoms (PMSs) have been considered as core features in the 
psychopathology of mood disorders and proved to have both diagnostic and prognostic 




PMSs remain fundamental signs in contemporary 
classifications of mental disorders and are included among the diagnostic criteria for 
Major Depressive Episodes (MDEs) in both DSM-5 and ICD-11. However, despite the 
clear neurophysiological differences between agitated and retarded depression, there is 
no distinction between the two patterns in such classifications. This approach has 
remained unchanged over the last 40 years although clinical findings clearly indicate the 
heterogeneity of depressive disorders 
2
. 
Parker and colleagues highlighted that PMSs should be considered the 
fundamental symptomatological characteristic of melancholia. They also found that the 
severity of PMSs has predictive value with regard to treatment outcome with 
electroconvulsive therapy (ECT) and tricyclic antidepressants (ADs) rather than 
selective narrow-action AD medications (e.g., serotonin uptake inhibitors) 
3
. However, 
the association between PMSs and melancholia may be partly tautological, and the 
linkage to treatment outcome could conceivably be associated with items influenced by 
melancholic manifestations that do not reflect psychomotor disturbance (e.g., cognitive 
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Psychomotor retardation (PR) has been reported as a major feature of depression, 
in particular in the melancholic subtype. PR was also found to be associated with 
bipolarity and with conversion from unipolar to bipolar depression in prospective 
follow-up. In this sense, PR might be an indicator of bipolarity in depressed patients 
4
. 
Nevertheless, several studies did not find differences in the rates of PR between major 
depressive and bipolar II disorder samples, but rather significantly higher rates of 
agitation among the group with bipolar II disorder 
5
. 
The concomitant presence in the same episode of psychomotor excitement and 
depression was originally classified by Kraepelin as a mixed episode. This view has 
been widely debated with some authors who agree that agitated depression is a mixed 
state 
6
 and others who argue that psychomotor agitation is just a manifestation of severe 
melancholia 
7
.  The nosological status of agitated depression is still unresolved and its 
nature is a matter of dispute 
8
, even if in the last decades a growing number of 
psychiatrists have considered agitated depression as a mixed state.  
Koukopoulos and Koukopoulos 
8
 proposed that agitated (mixed) depression 
consisted in the presence of depressed mood associated with at least two symptoms 
among inner tension, psychomotor agitation (PA), and racing/crowded thoughts which 
worsened with AD treatment 
9
. A recent study validated the diagnostic criteria proposed 
by Koukopoulos for mixed depression, corroborating their nosological validity 
10
. 
Several reports indicate that agitated depression in MDEs could be related to the bipolar 
spectrum and more specifically to a bipolar mixed state, stressing the excitatory nature 
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The aim of the present pooled post-hoc analysis was to further investigate PMSs 
in a large multinational sample of patients with MDE, comparing clinical features 
among patients with PA, PR, and patients without psychomotor symptoms (NPS) and 




The present pooled post-hoc analysis evaluated data from two international 
multicentre, non-interventional, cross-sectional studies, the BRIDGE 
15
 and the 
BRIDGE-II-MIX 
16
. This is the first analysis based on a pooled cohort from BRIDGE 
and BRIDGE-II- MIX studies. 
In summary, the BRIDGE (Bipolar Disorders: Improving Diagnosis, Guidance 
and Education) study was a large, cross-sectional diagnostic investigation of 5635 
depressed patients conducted in 18 countries in Europe, Asia and North Africa, between 
April 2008 and May 2009. The BRIDGE study applied a descriptive, bottom-up 
approach to detect hypo/mania in patients with a MDE 
15
. 
The BRIDGE-II-MIX Study 
16
 was a multicentre, international, non-
interventional, cross-sectional study conducted between June 2009 and July 2010 in 239 
centres in Bulgaria, Egypt, Morocco, Netherlands, Portugal, Russia, Spain and Turkey. 
A total of 2811 patients gave their written informed consent and provided complete 
data. The number of investigators per country ranged from 62 in Spain to 18 in Egypt. 
Each centre was expected to enrol 10 to 20 consecutive patients consulting for a MDE 
during a 3-months recruitment period. The primary objective of the BRIDGE-II-MIX 
study was to establish the frequency of depressive mixed states by analysing all the 
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 Participants included in both cohorts were adults aged 18 or older, diagnosed 
with MDE according to DSM IV-TR diagnostic criteria at the time of the consultation. 
Patients presenting with an acute non-psychiatric condition were excluded.  
The two samples were totally independent from each other. The two databases 
have been merged because similar in the methodology of investigation and the explored 
clinical variables.  
The specific case report form (CRF) for each study have been independently 
revised by two investigators (CM and MB) and the variables assessing the same features 
in the two CRF have been selected for inclusion in the pooled dataset. Continuous 
variables, namely age and global assessment of functioning (GAF) score, similarly 
reported in both study have been merged. Age at first psychiatric symptom, age at first 
setting of depressive diagnosis, total number of mood and depressive episodes in the 
past, total number of hospitalizations, duration of the current episode, that were coded 
in ranges in the BRIDGE study, have been converted into the same ranges in the 
BRIDGE-II-MIX study in order to obtain a comparable ordinal variable between the 
datasets. The variables assessed only in one of the two samples, i.e. mixed features of 
the depressive episode, weight, height, smoking status, postpartum depression, clinical 
global impression (CGI) scale, illness progression (mood episodes with/without free 
intervals), all the items from the self-questionnaire assessing mixed features, have been 
excluded. The two databases have been merged using the specific SPSS tool and have 
been subsequently independently revised by two investigators (CM and MB).  
 Both studies were conducted according to the Declaration of Helsinki (Hong 
Kong Amendment), Good Epidemiologic Practice, and the International 
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epidemiologic research, as well as pertinent national legal and regulatory requirements. 
For both studies, written informed consent was obtained from each patient. The 
protocols have been submitted and approved by the appropriate local ethics committee 
in each country.  
 The sample consisted of 8496 patients with a MDE. Patients diagnosed with 
borderline personality disorder (BPD) (n=719) have been excluded from the analysis in 
order to control for the possible bias represented by PA as a trait-like characteristic of 
BPD. For the same reason, patients presenting Attention Deficit Hyperactivity Disorder 
comorbidity (n=88) have been excluded. Patients with anxiety disorders or 
alcohol/substance abuse may present psychomotor changes at certain stages of the 
disease, however we cannot assume that psychomotor symptoms are stable to such an 
extent they could represent a biasing factor. The final total sample of the present post-
hoc analysis was composed by 7689 patients. 
 
Data collection 
For both studies, community and hospital-based psychiatrists recruited 
consecutively all eligible adult (18 years or older) patients with a diagnosis of MDE. 
Patients were assessed in a single visit by the participating psychiatrists with a 
structured protocol covering socio-demographic variables, clinical features, family 
history, treatment and comorbid psychiatric disorders. Psychiatric diagnoses were based 
on DSM-IV-TR. For a better detection of BD patients, criteria for bipolarity proposed 
by Angst et al. 
17
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The presence of PA and PR has been clinically evaluated, according to the 
corresponding definitions of the DSM-IV-TR. PA is defined as the presence of 
excessive, non-productive and repetitious motor activity (such as restlessness, pacing, 
fidgeting, etc.) associated with a feeling of inner tension. Conversely, PR is a visible 
generalized slowing of movements and speech.  
Bipolarity specifier criteria 
15,18
 attribute a diagnosis of BD in patients who 
experienced an episode of elevated mood, an episode of irritable mood, or an episode of 
increased activity with  at least 3 of the symptoms listed under Criterion B of the DSM-
IV-TR associated with at least 1 of the 3 following consequences: (1) unequivocal and 
observable change in functioning uncharacteristic of the person’s usual behaviour, (2) 
marked impairment in social or occupational functioning observable by others, or (3) 
requiring hospitalization or outpatient treatment.  No minimum duration of symptoms 
was required and no exclusion criteria were applied. Functional status was determined 
in both studies by the physician, using the GAF scale 
19
. 
 The evaluation protocol was explicitly structured to use skills that fully trained 
psychiatrists would have and routinely apply in conducting an initial evaluation of a 
patient. No rating scales requiring calibration with a standard were incorporated. The 
evaluators were instructed to follow their usual practice, as training might alter these 
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Statistical analysis 
Chi-square test was used for comparison between groups for categorical variables 
and ANOVA test with post-hoc Tukey comparison test for continuous variables. The 
bivariate analysis involved many tests of statistical significance, raising the problem of 
type I errors. For this reason, we corrected for multiple comparisons and utilized a 
Bonferroni-corrected threshold for statistical significance. Three stepwise backward 
logistic regression models were then used to identify the predictive value of the clinical 
characteristics on the presence of PA versus (vs.) PR, PA vs. NPS, PR vs. NPS. An 
alpha of 0.05 in the bivariate comparison was utilized as the cut-off for the inclusion of 
a variable in the regression model. The stepwise modelling procedure started with the 
full model and consisted, for each step, in eliminating the least statistically significant 
variable from the model and re-computing the revised model, until all remaining 
variables were at p<0.1. Odds ratios with 95% confidence intervals were used for 
observed associations. We used the statistical routines of SPSS Statistics 23.0 for 
Windows (SPSS Inc., USA). 
 
Results 
Focusing on Psychomotor patterns, we divided the whole sample of MDE patients 
(n=7689) into 3 subgroups: the PR group (n= 3720), the PA group (n=1971) and the 
NPS group (n=1998). We compared the 3 subgroups with each other, considering 
demographical and clinical variables such as age, gender, familial history of BD, 
clinical course of the illness, psychiatric comorbidity, GAF, previous treatments and 
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Comparisons between PR and NPS patients  
PR and NPS subgroups did not show significant differences in gender distribution 
(female gender respectively, 66.8% and 64.8%) (Table 1). Conversely, PR patients 
showed significantly higher mean age at the moment of the evaluation (45.6 years old) 
than NPS patients (43.5 years old) (Table 2). The age at first MDE was similar in the 
two subgroups, while a higher rate of first-degree family history of BD was found 
within the PR patients in comparison to NPS patients (respectively, 14.7% and. 12.7%) 
(Table 1). PR subjects had also significantly higher rates of manic/hypomanic switches 
with ADs (17.6%) compared to the NPS group (14.3%). Likewise, PR patients had 
more frequently ≥3 lifetime MDEs (51.3% vs. 42.2%), atypical features (16.9% vs. 
14.5%) and psychotic features (9.8% vs. 5.9%) than NPS patients. On the contrary, a 
history of suicide attempts and the rate of current MDE duration less than 1 month were 
similar in the two groups. No differences were found in the two groups regarding 
psychiatric comorbidities, such as anxiety disorders and alcohol-substance use 
disorders. Considering pharmacological treatments, PR patients were more frequently 
treated with antipsychotics (respectively 34.5% and 26%) and mood stabilizers (33% 
and 28.4%) than the NPS patients, while no significant differences were found for ADs 
use and ECT. 
 
As for diagnostic distribution, 591 (15.9%) patients in the PR group and 242 
(12.2%) patients in NPS group fulfilled DSM IV-TR criteria for BD, showing a 
statistically significant difference. When considering criteria for bipolarity proposed by 
Angst, we also found a significant difference between PR and NPS groups (respectively 
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The GAF score was significantly higher in the NPS group (mean 54.3, ds=14.4) 
than in the PR group (mean 51.0 ds=14.4) (Table 2). 
In the multivariate logistic regression analysis, the variables significantly 
associated with PR were the higher mean age at the evaluation, a clinical history of 3 or 
more MDEs, psychotic features, previous treatment with antipsychotics, a lower global 
functioning, measured with the GAF scale, and a diagnosis of BD according to DSM-
IV-TR criteria (Table 3). 
 
Comparisons between PA and NPS 
Gender distribution and mean age at the moment of evaluation were similar in PA 
and NPS subgroups (Table 1 and 2). We found significant differences regarding the 
early onset  of the first MDE (<30 years old) in the PA patients compared to NPS 
patients (respectively 42.1% vs. 35.4%). Moreover, significant higher rates of first-
degree family history of BD (19.3% vs. 12.7%), manic/hypomanic switches with ADs 
(21.5% vs. 14.3%), presence of atypical (20.0% vs. 14.5%) and psychotic (18.4% vs. 
5.9%) features, ≥3 lifetime MDEs (48.9% vs. 42.2%), current MDE duration less than 1 
month (34.1% vs. 29.8%) and history of suicide attempts (26.7% vs. 21.2%) were found 
in the PA group compared to NPS patients. 
Regarding the presence of psychiatric comorbidities, patients in the PA group 
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As for current treatments, we found a higher use of antipsychotics (38.2% vs. 
26.0%), mood stabilizers (40.6% vs. 28.4%) and ECT (4.4% vs. 2.2%) in the PA group 
compared to the NPS group, whilst no significant differences were found amongst the 
two groups regarding ADs use. As for BD diagnosis, PA subjects fulfilled significantly 
more often DSM-IV criteria compared to NPS patients (respectively 18.6% vs. 12.2%). 
Likewise, PA patients showed higher rates of bipolarity, according to the criteria 
proposed by Angst et al. The global functioning was significantly lower in PA patients 
compared to NPS subjects. 
In the multivariate logistic regression analysis, the clinical features that 
significantly differentiated PA from NPS patients were family history of BD, the 
presence of current atypical depression, psychotic features, comorbidity with anxiety 
disorders, treatment with antipsychotics and mood stabilizers, a diagnosis of BD 
according to DSM IV-TR criteria, along with lower GAF scores (Table 3). 
 
Comparison between PA and PR 
PA and PR patients differed significantly in terms of mean age at the index 
episode (respectively, 43.6 vs. 45.6), GAF score (49.9 vs. 51) (Table 2) and family 
history of BD (19.3% vs. 14.7%) (Table 1). Concerning clinical variables, significant 
differences were found amongst PA and PR patients in the early onset of the first MDE 
(respectively, 42.1% vs. 34.1%), the presence of manic/hypomanic switches with ADs 
(21.5% vs. 17.6%), atypical features (20.0% vs. 16.9%), psychotic features (18.4% vs. 
9.8 %), the presence of lifetime suicide attempts (26.7% vs. 22.8%) and current episode 
duration less than 1 month (34.1% vs. 30.5%). The two groups did not differ as regard 
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higher in the PA group, showing higher rates of anxiety disorders (26.8% vs. 19.4%) 
and alcohol-substance use disorder (5.4% vs. 4.7%) in comparison to PR group. The 
two groups significantly differed regarding the use of antipsychotics, mood stabilizers 
and ECT that resulted more frequently administered in patients with PA compared to 
PR patients (respectively 38.2% vs. 34.5%, 40.6% vs. 33.0% and 4.4% vs. 2.6%). 
Regarding the diagnostic distribution in the two groups, PA and PR showed statistical 
difference if both DSM-IV criteria (18.6% vs. 15.9%) and criteria for bipolarity 
proposed by Angst (49.7% vs. 42.8%) are considered (Table 1). 
Using multivariate logistic regression analysis, the characteristics significantly 
related to the presence of PA were early onset of first MDE, atypical depression, 
psychotic features, comorbidity with anxiety disorders, treatment with mood stabilizers 
and ECT as well as the presence of Angst’s specifier for bipolarity (Table 3). 
 
Discussion 
In this pooled post-hoc analysis of BRIDGE and BRIDGE-II-MIX studies, our 
results indicate that PMSs represent common clinical features during a MDE, occurring 
in almost three out of four patients, as reported in previous studies 
20
. 
Several findings from the present study seem to support our expected hypothesis 
of the inclusion of patients with PMSs (PA and PR) within the rubric of BD. First, we 
found significantly higher rates of BD diagnosis in the PA and PR groups compared to 
the NPS group using both DSM IV-TR and bipolar specifier criteria. Moreover, the PA 
and PR groups reported higher frequencies of clinical and course variables, such as 
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psychotic features and higher rates of more than 3 lifetime MDEs, which have been 
recognized as the most relevant clinical indicators of bipolarity in depressed patients 
15,17,21,22
. By comparing the two “psychomotor” subgroups (PA and PR), we found that 
patients with agitated depression presented more frequently most of the clinical and 
course variables associated with a “bipolar diathesis”, such as a family history of BD, 
manic/hypomanic switches with ADs, atypical and psychotic features.  
Furthermore, the PA group was significantly associated with an early onset of 
first MDE and with a worse course of illness compared to PR and NPS groups. In fact, 
PA patients presented more often anxiety and alcohol-substances use comorbidities 
along with higher frequencies of suicide attempts, indicating a more severe and 
difficult-to-treat subtype of patients. The role of PA in suicidal behaviours has been 
investigated in several studies highlighting the relationship between anxiety, 
psychomotor activation, suicide attempts and the mixed element during a MDE 
13,23–25
. 
In this context, PA might be considered as a core dimension in depressed patients with 
mixed features and it could be seen as a part of the construct associated with suicidal 
behaviours in depressed BD and major depressive disorder patients. Noteworthy, 
despite several previous studies emphasized the importance of PA as a mixed element, 
associated with an increased risk of suicide behaviours 
25
, currently PA is not included 
among the criteria for “mixed features” specifier for a depressive episode in DSM-5.  
 
Interestingly, we found a broadly more severe impairment in the global 
functioning among patients with PMSs compared to the NPS group. This is in 
agreement with previous studies that highlighted a globally more severe impact on 
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between retardation and agitation 
26
. In our post-hoc analysis, the PA group showed 
significantly lower mean GAF scale scores compared with the PR group, indicating a 
poorer functional outcome in this subgroup of patients. 
It is noteworthy that in our sample, the PA and PR groups compared with the 
NPS group, and the PA group compared separately with the PR group, had higher 
frequency of antipsychotics and mood stabilizers use, reinforcing the hypothesis of a 
greater association of PMSs with bipolarity and treatment complexity 
27
. After multiple 
logistic regressions, we found that treatment with mood stabilizers was mostly predicted 
by the presence of PA, possibly indicating a stronger association of bipolarity features 
with this depressive subtype. In other words, patients with PA seem to belong to a 
difficult-to-treat subgroup of depressed patients that require more complex 
pharmacological treatment. In the same line is the observation that ECT, frequently 
used in treatment-resistant depression, resulted to be more frequently used in patients 
with PA than in the other groups.  
In the multiple logistic regression models, the presence of psychotic symptoms, 
the DSM IV-TR diagnosis of BD and the impairment in global functioning predicted 
both PA and PR. Interestingly, the variables that significantly differentiated PA from 
PR were some of the clinical features most associated with a bipolar diathesis, such as 
early onset of first MDE, atypical depressive features, psychotic features and a higher 
BD diagnosis according to the bipolar specifier 
18
. These results corroborate the 
evidence for the association between MDE with PMSs and bipolarity. Furthermore, 
among the depressive syndromes with PMSs, those characterized by PA are the most 
closely related to bipolarity and seem to belong to a difficult-to-treat subgroup, 
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Historically, MDEs with psychomotor agitation were classified by Kraepelin 
among the depressive forms of mixed state and characterized by the contemporary 
presence of depressive symptoms and different elements of psychomotor excitement 
28,29
. Although the classification of agitated depression is still a matter of debate, in the 
last decades a growing number of studies supported the view that agitated depression is 
more closely aligned with the mixed phase of BD 
23,30,31
. In this vein, a possible 
alternative interpretation of our results is that the presence of PA in depressive states 
contradicts the bipolar/unipolar distinction. As Kraepelin 
28
 and Koukopoulos 
9
 held, 
mixed states are actually very common and thus it is not feasible to divide mood 
disorders into bipolar and unipolar types. “Manic-depressive illness” should be viewed 
as a continuum of forms that presents either as depression or mania or, most commonly, 
both.  
The principal strengths of the present post-hoc analysis include the large sample 
size, obtained by pooling BRIDGE and BRIDGE-II -MIX cohorts, and the wide range 
of worldwide care settings encompassed. The studies included hospital and community 
psychiatrists 
15,16
. This broad, local clinical practice–relevant sample likely increases the 
generalizability of the findings. One limitation is that the participating centres were not 
randomly selected, which may have led to a bias through the inclusion of psychiatrists 
with a particular interest in BD who, as a result, look more carefully for psychomotor 
symptoms and are more likely to rate them as such. This may be seen, however, as a 
positive point, in the sense that some expertise is needed to detect past hypomanic 
symptoms and psychomotor abnormalities. Notwithstanding this, a random selection of 
participants would not have been possible because lists of all practicing physicians were 
not in the public domain for the participating countries. Another limitation is the widely 
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(BRIDGE) and from 1.0% to 57.8% (BRIDGE-II-MIX), which reflect clinical practices 
in the respective countries, and hospitalization rates were not associated with significant 
differences in rates of PMS. Finally, in the present study, the possible role of 
pharmacological treatments in the induction of PMS has not been directly evaluated, 
however the association of PA with increased rate of antipsychotic and mood stabilizer 
drugs seems to suggest a minor influence of treatments on PMS.  
In conclusion, our results seem to support the hypothesis that the presence of different 
patterns of PMSs during a MDE has important diagnostic, prognostic and therapeutic 
implications with a possible discriminative validity for distinguishing bipolar from 
unipolar depression. In addition, our study shows some important clinical and course 
differences between patients with psychomotor agitation and retardation, possibly 
suggesting the need to modify the DSM-5 diagnostic criteria for MDE which currently 
merge into a single criterion the two different motor patterns. 
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Table 1. Clinical Features in 7689 patients with Major Depressive Episode (MDE): comparisons among patients with Psychomotor Agitation 











PR vs. NPS  
OR (95% CI) 
PA vs. NPS  
OR (95% CI) 
PA vs. PR 
OR (95% CI) 
Female gender 2478 (66.8%) 1262 (64.2%) 1289 (64.8%) 1.09 (.98-1.23) .98 (.86-1.11) .89 (.80-1.00)  
First MDE <30 years 1257 (34.1%) 824 (42.1%) 698 (35.4%) .94 (.84-1.06) 1.33 (1.17-1.51) 1.40 (1.26-1.57) 
First MDE >60 years 157 (4.3%) 67 (3.4%) 86 (4.4%) .98 (.75-1.28) .78 (.56-1.07)  .80 (.56-1.07)  
First-degree Family History BD 540 (14.7%) 375 (19.3%) 250 (12.7%) 1.18 (1.01-1.39) 1.65 (1.38-1.96) 1.39 (1.20-1.61) 
Manic/hypomanic switch with AD 629 (17.6%) 399 (21.5%) 270 (14.3%) 1.28 (1.09-1.49) 1.64 (1.38-1.94) 1.28 (1.11-1.48) 
Atypical features 627 (16.9%) 394 (20.0%) 289 (14.5%) 1.2 (1.03-1.39) 1.48 (1.25-1.74) 1.23 (1.07-1.42) 
Psychotic features 363 (9.8%) 362 (18.4%) 118 (5.9%) 1.72 (1.39-2.14) 3.59 (2.82-4.46) 2.08 (1.78-2.44) 
3 or more MDEs 1901 (51.3%) 960 (48.9%) 841 (42.2%) 1.44 (1.3-1.61) 1.31 (1.15-1.48) .91 (.81-1.01) 
Current episode <1 month  1116 (30.5%) 662 (34.1%) 583 (29.8%) 1.03 (.92-1.17)  1.22 (1.06-1.39) 1.18 (1.05-1.32) 
Suicide attempts 848 (22.8%) 525 (26.7%) 424 (21.2%) 1.1 (.96-1.25) 1.35 (1.16-1.56) 1.23 (1.08-1.57) 
Psychiatric comorbidity 
Anxiety Disorders 717 (19.4%) 525 (26.8%) 364 (18.4%) 1.07 (.93-1.23) 1.63 (1.4-1.9) 1.52 (1.34-1.73) 
Alcohol-substance Use Dis. 175 (4.7%) 106 (5.4%) 80 (4.1%) 1.17 (.89-1.54) 1.35 (1.0-1.81)  1.15 (0.9-1.60) 
Treatment 
ADs 3272 (88.0%) 1727 (87.6%) 1758 (88.0%) .99 (.84-1.18) .97 (.80-1.17) .97 (.82-1.14) 
Antipsychotics 1282 (34.5%) 773 (38.2%) 520 (26.0%) 1.49 (1.32-1.69) 1.83 (1.6-2.1) 1.23 (1.1-1.37) 
Mood-stabilizers 1228 (33.0%) 800 (40.6%) 567 (28.4%) 1.24 (1.1-1.4) 1.72 (1.51-1.97) 1.39 (1.24-1.55) 
ECT 96 (2.6%) 87 (4.4%) 43 (2.2%) 1.2 (.84-1.73) 2.1 (1.45-3.04) 1.74 (1.30-2.34) 
Diagnostic distribution of BD 
BD (DSM-IV-TR) 591 (15.9%) 364 (18.6%) 242 (12.2%) 1.36 (1.16-1.6) 1.64 (1.38-1.97) 1.21 (1.04-1.39) 
BD (Specifier) 1591 (42.8%) 976 (49.7%) 771 (38.6%) 1.19 (1.06-1.33) 1.57 (1.38-1-78) 1.32 (1.18-1.47) 
BD (DSM-IV-TR and Specifier) 455 (12.3%) 312 (15.9%) 194 (9.8%) 1.29 (1.08-1.54 1.75 (1.44-2.12) 1.36 (1.16-1.59) 
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Table 2. ANOVA univariata test for age at clinical evaluation and Global Assessment of Functioning 
(GAF) score in patients with Psychomotor Agitation (PA), Psychomotor Retardation (PR) and without 
motor symptoms (NPS). 
 PA PR NPS p 
GAF mean; (sd) 49.9 (14.5) 51.0 (14.4) 54.3 (13.5) <0.001 
Age mean; (sd) 43.6 (13.6) 45.6 (13.9) 43.5 (13.5) <0.001 
Post-hoc comparisons using the Tukey test 
GAF: NPS > PR > PA 
NPS > PR (3.332, 95%-CI [2.4-4.26]) 
NPS > PA (4.415, 95%-CI [3.35-5.48]) 
PR > PA (1.083, 95%-CI [0.15-2.01]) 
Age: PR > NPS > PA 
PR > NPS (2.049, 95%-CI [1.16-2.94]) 
PR > PA (1.996 95%-CI [1.1-2.89]) 
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OR (95% CI) 
PA vs PR
‡ 
OR (95% CI) 
Age 1.01 (1.00-1.01) - 0.99 (1.0-1.38) 
Female gender - -  
First MDE <30 years - - 1.19 (1.02-1.38) 
First MDE >60 years - - - 
First-degree family history of BD - 1.29 (1.06-1.57) 1.15 (0.98-1.35) 
Manic/hypomanic switches with ADs - - - 
Atypical features - 1.41 (1.17-1.70) 1.18 (1.01-1.38) 
Psychotic features 1.30 (1.03-1.64) 2.47 (1.93-3.16) 1.95 (1.65-2.31) 
3 or more MDEs 1.22 (1.08-1.38) - - 
Current episode <1 month  - - - 
Suicide attempts - - - 
Anxiety disorders - 1.66 (1.41-1.96) 1.52 (1.32 -1.74) 
Alcohol-substance use disorder - - - 
ADs - - - 
Antipsychotics 1.28 (1.12-1.46) 1.32 (1.12-1.54) - 
Mood-stabilizers - 1.33 (1.13-1.55) 1.2(1.05-1.37) 
ECT -  1.64 (1.18- 2.29) 
Bipolar Disorder (DSM-IV-TR) 1.21 (1.02-1.43) 1.22 (0.99-1.50) - 
Bipolar Disorder (Specifier) - - 1.13 (1.00-1.30) 
GAF 0.99 (0.98-0.99) 0.99 (0.98- 0.99) - 
NPS, no psychomotor symptoms; PA, Psychomotor Agitation; PR, Psychomotor Retardation; MDE, Major Depressive Episode; BD, Bipolar Disorder; AD, Antidepressant; ECT, Electroconvulsive therapy; DSM, 
Diagnostic and Statistical Manual of Mental Disorder; GAF, Global Assessment of Functioning;  
*Chi-square= 134,598, df=6; p<0.001; variables not in the equation: mood-stabilizers, manic/hypomanic switches with ADs, atypical features, first degree family history of BD. 
†Chi-square= 134,598 df=8; p<0.001; variables not in the equation: manic/hypomanic switches with ADs, current episode<1month, suicide attempts, 3 or more MDEs, first MDE<30 years, ECT. 
‡Chi-square=189,051, df=9; p<0.001; variables not in the equation: GAF, manic/hypomanic switches with ADs, antipsychotics, current episode<1month, age, bipolar disorder (DSM IV TR), suicide attempts.  
